/
Navigation
Chronicles
Browse all articles
Explore
Semantic exploration
Research
Entity momentum
Nexus
Correlations & relationships
Story Arc
Topic evolution
Drift Map
Semantic trajectory animation
Posts
Analysis & commentary
Pulse API
Tech news intelligence API
Browse
Entities
Companies, people, products, technologies
Domains
Browse by publication source
Handles
Browse by social media handle
Detection
Concept Search
Semantic similarity search
High Impact Stories
Top coverage by position
Sentiment Analysis
Positive/negative coverage
Anomaly Detection
Unusual coverage patterns
Analysis
Rivalry Report
Compare two entities head-to-head
Semantic Pivots
Narrative discontinuities
Crisis Response
Event recovery patterns
Connected
Search: /
Command: ⌘K
Embeddings: large
TEXXR

Chronicles

The story behind the story

days · browse · Enter similar · o open

Glooko, whose diabetes management app is used by more than 4.4M patients and 10K clinics globally, raised a $100M Series F led by Georgian

Conor Hale / Fierce Biotech :

Fierce Biotech Conor Hale

Context & Ripple Effects

Glooko’s round extends a recurring funding pattern in diabetes-management software: Livongo previously raised a $105M Series E for a connected-device and cloud platform, while Virta Health raised $65M for a monitoring- and counseling-led model.

The $100M Series F stands out because Glooko already reports use by more than 4.4 million patients and 10,000 clinics globally. It places new growth capital behind an established care-delivery footprint rather than an early-stage consumer app alone.

First-order effects

  • Glooko gains $100M in Series F financing, led by Georgian, to support the company serving its existing patient and clinic base.
  • Georgian becomes the lead investor in a later-stage diabetes-management software company with reported global clinical adoption.

Second-order effects

  • The round reinforces a high capital benchmark for diabetes-management platforms, including companies built around connected monitoring, telehealth, or metabolic-health software such as glucose-monitoring app provider Levels.
  • Healthcare providers and device or drug companies evaluating digital patient tools may have another well-funded platform to compare with app-building infrastructure providers such as BrightInsight.

Third-order effects

  • If later-stage funding continues to concentrate in platforms with both patient scale and clinic distribution, diabetes software could increasingly compete on integration into care workflows rather than app features alone.
  • The pattern points toward a more segmented market: broad clinical-management platforms alongside consumer insight products and condition-specific telehealth services, though the corpus does not establish which model will consolidate demand.

The trend: Diabetes digital-health investment is moving toward established platforms that combine patient engagement with clinical distribution and connected-data workflows.